These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Kars M; Pereira AM; Bax JJ; Romijn JA Eur J Endocrinol; 2008 Oct; 159(4):363-7. PubMed ID: 18703568 [TBL] [Abstract][Full Text] [Related]
8. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas. Yarman S; Kurtulmus N; Bilge A Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095 [TBL] [Abstract][Full Text] [Related]
9. Cabergoline use for pituitary tumors and valvular disorders. Auriemma RS; Pivonello R; Ferreri L; Priscitelli P; Colao A Endocrinol Metab Clin North Am; 2015 Mar; 44(1):89-97. PubMed ID: 25732645 [TBL] [Abstract][Full Text] [Related]
10. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Yamamoto M; Uesugi T; Nakayama T Neurology; 2006 Oct; 67(7):1225-9. PubMed ID: 17030757 [TBL] [Abstract][Full Text] [Related]
11. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Delgado V; Biermasz NR; van Thiel SW; Ewe SH; Marsan NA; Holman ER; Feelders RA; Smit JW; Bax JJ; Pereira AM Clin Endocrinol (Oxf); 2012 Jul; 77(1):99-105. PubMed ID: 22211510 [TBL] [Abstract][Full Text] [Related]
12. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. Kars M; Pereira AM; Smit JW; Romijn JA Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180 [TBL] [Abstract][Full Text] [Related]
15. Bromocriptine use and the risk of valvular heart disease. Tan LC; Ng KK; Au WL; Lee RK; Chan YH; Tan NC Mov Disord; 2009 Feb; 24(3):344-9. PubMed ID: 18989898 [TBL] [Abstract][Full Text] [Related]
16. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Elenkova A; Shabani R; Kalinov K; Zacharieva S Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808 [TBL] [Abstract][Full Text] [Related]
17. Update in prolactinomas. Kars M; Dekkers OM; Pereira AM; Romijn JA Neth J Med; 2010 Mar; 68(3):104-12. PubMed ID: 20308704 [TBL] [Abstract][Full Text] [Related]
18. [Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?]. Roth J; Ulmanová O; Růzicka E Cas Lek Cesk; 2005; 144(2):123-6. PubMed ID: 15807300 [TBL] [Abstract][Full Text] [Related]